BEND3P3: A Promising Potential Drug Target and Biomarker (G650623)

Target Name: BEND3P3

NCBI ID: G650623

BEND3P3

Other Name(s): BEN domain containing 3 pseudogene 3

BEND3P3: A Promising Potential Drug Target and Biomarker

Introduction

The identification of potential drug targets and biomarkers is a critical step in the development of new therapeutic approaches for various diseases. One of the promising targets in the field of cancer research is the BEN domain containing 3 pseudogenes (BEND3P3), which has been identified as a potential drug target and biomarker. In this article, we will explore the BEND3P3 protein, its function, potential drug targets, and its potential as a biomarker for cancer diagnosis and treatment.

Structure and Function

The BEN domain is a conserved region that is found in various proteins, including DNA-binding proteins, RNA-binding proteins, and protein-protein interaction proteins. The BEN domain is characterized by a specificity loop and a long terminal extension that contains a hydrophobic Amino acid residue and a negatively charged amino acid residue, known as an electrostatic potential.

The BEND3P3 protein is a 19 kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is composed of a unique alternating between a cytoplasmic and a nuclear localization pattern. The cytoplasmic region of the protein contains the N -terminus, the catalytic domain, and the C-terminus. The nuclear localization domain is located in the middle of the protein and is composed of the BEN domain, the alpha-helix, and the beta-sheet.

The BEND3P3 protein plays a crucial role in various cellular processes, including cell adhesion, migration, and invasion. It is involved in the regulation of cell-cell adhesion by interacting with various cell surface molecules, such as cadherins and integrins. BEND3P3 has also been shown to be involved in the regulation of cell migration and invasion, as well as in the regulation of cell survival.

Potential Drug Targets

The BEND3P3 protein is a potential drug target due to its unique structure and function. Several studies have identified potential drug targets in the BEND3P3 protein, including the BEN domain containing 3 pseudogenes (BEND3P3). These pseudogenes are located in the N-terminus of the protein and are involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion.

The first potential drug target identified for BEND3P3 is the BEN domain containing 3 pseudogenes (BEND3P3) gene. This gene encodes a protein that contains the BEN domain and is expressed in various tissues, including brain, heart, liver, and pancreas. Several studies have shown that overexpression of the BEND3P3 gene leads to the formation of BEND3P3 fusions, which are hyperactive and can cause various cellular abnormalities, including cancer. Therefore, targeting the BEND3P3 gene and its BEN domain containing 3 pseudogenes may be an effective strategy for the development of new therapeutic approaches for cancer.

Another potential drug target for BEND3P3 is the interaction of the BEND3P3 protein with various cell surface molecules, such as cadherins and integrins. Several studies have shown that the BEND3P3 protein can interact with these molecules and regulate their activity, which may have implications for the regulation of cell-cell adhesion and migration. Therefore, targeting the interaction between the BEND3P3 protein and cell surface molecules may be an effective strategy for the development of new therapeutic approaches for cancer.

Potential Biomarkers

The BEND3P3 protein has also been identified as a potential biomarker for cancer diagnosis and treatment. Several studies have shown that the BEND3P3 protein can be used as a biomarker for various types of cancer, including neuro

Protein Name: BEN Domain Containing 3 Pseudogene 3

The "BEND3P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BEND3P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets